ASTER-DM-HEALTHCARE
11.4.2022 15:59:12 CEST | Business Wire | Press release
Aster Guardians Global Nursing Award has just announced its top 10 finalists hailing from across the world. These nurses have been selected from over 24,000 nurses who applied from over 184 countries, through a stringent review process run independently by Ernst & Young LLP, a Screening Jury and a Grand Jury. All applications were evaluated to create a shortlist of 181 which underwent further review to put forward 41 top applications. These 41 applications were then reviewed by the Grand Jury to announce the top 10 finalists. All applicant nurses were asked to submit their applications based on four areas of contribution: Leadership, Research/Innovation, Patient Care and Society/Community Service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005418/en/
The top 10 finalists, who will now undergo further evaluation to claim the grand prize of USD 250,000, are: Anna Qabale Duba from Kenya; Dida Jirma Bulle from Kenya; Francis Michael Fernando from United Kingdom; Jasmine Mohammed Sharaf from United Arab Emirates; Julia Dorothy Downing from United Kingdom; Lincy Padicala Joseph from India, Manju Dhandapani from India; Matthew James Ball from Australia; Rachel Abraham Joseph from United States and Wais Mohammad Qarani from Afghanistan . To know more about the top 10 finalists, please visit: https://www.asterguardians.com/ .
Speaking on the top 10 finalists and the upcoming award ceremony to be held on 12th May – International Nurses Day, at The Atlantis, Dubai, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said , “With over 7000 nurses as the main pillar of our organization, we at Aster witness their commitment and compassion every single day. During this pandemic, their critical contribution with dedication and sacrifice, putting their own safety and lives at risk, was brought to the forefront globally. We thought that it is appropriate to institute a global level award for the nurses to recognize the members of this noble profession. With over 24,000 nurses who applied, we are overwhelmed by the response received from different parts of the world for the inaugural edition of Aster Guardians Global Nursing Award. It has been a hard task for the eminent Jury members to shortlist the top 10 extraordinary nurses from the large number of applicants. We wish the finalists nominated in the top 10 all the very best for the final evaluation process.”
While one winner will be awarded the grand prize of USD 250,000, the other nine finalists will receive a monetary award. The final round will consist of public voting for each of the nurses starting from 26th April and in-person interview with the Grand Jury members consisting of Mr. Howard Catton - Chief Executive Officer, International Council of Nurses, Switzerland; Prof. Sheila Tlou - Co-Chairperson, Global HIV Prevention Coalition and Ex - Minister of Health & Member of Parliament – Govt. of Botswana; Prof. James Buchan - Adjunct Professor, WHO Collaborating Centre for Nursing; Mr. Muralee Thummarukudy, Acting Head, Resilience to Disasters and Conflicts Global Support Branch, United Nations Environment Programme, Switzerland; and Dr. Carolyn Gomes, Executive Director, Caribbean Vulnerable Communities Coalition (CVC), Jamaica.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well."
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom